Article Text
PostScript
Correspondence
Does the purported mortality benefit of beta-blocker therapy in heart failure with a preserved ejection fraction apply to patients without prior myocardial infarction?
Statistics from Altmetric.com
To the Editor We read with interest the study by Zheng et al in which the authors conducted a meta-analysis of randomised controlled trials to evaluate the effect of different drug classes in heart failure with a preserved ejection fraction (HFpEF). Primary outcome was all-cause mortality and secondary outcome was cardiovascular mortality among other secondary outcomes. The authors found that beta-blocker therapy led to significant reductions in all-cause …
Footnotes
Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent Not required.
Provenance and peer review Not commissioned; internally peer reviewed.
Linked Articles
- Heart failure and cardiomyopathies